FDG-PET/CT in Breast Cancer
Breast cancer is the most common cancer in women worldwide and it is still one of the leading causes of morbi-mortality, therefore being a major concern. 2-FDG PET/CT is commonly […]
Free
Breast cancer is the most common cancer in women worldwide and it is still one of the leading causes of morbi-mortality, therefore being a major concern. 2-FDG PET/CT is commonly […]
The webinar will cover the most relevant methodological aspects of nuclear medicine techniques in paediatric nephrourology, with particular attention to the choice of the radiotracer, the correct patient preparation, and […]
The rapid development in machine learning has generated new artificial intelligence (AI) based methods for improving dosimetry within nuclear medicine. This webinar will present the current status of AI within […]
While PET imaging with radionuclides such as F18 and Ga68 have proven to provide high quality diagnostic imaging, imaging with other radionuclides can be more challenging. Zr-89 is one such […]
The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However, due to differences in […]
With the arrival of new therapeutic tracers, nuclear medicine has a new arsenal to treat metastatic bone pain. This presentation aims to give the keys to define the place of […]
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
European School of Multimodality Imaging & Therapy (ESMIT)
Schmalzhofgasse 26
1060 Vienna
Austria
phone +43 1 890 44 27
e-mail esmit@eanm.org